ATE147750T1 - Phosphotriester-typ biologisch-aktiver verbindungen - Google Patents

Phosphotriester-typ biologisch-aktiver verbindungen

Info

Publication number
ATE147750T1
ATE147750T1 AT93910147T AT93910147T ATE147750T1 AT E147750 T1 ATE147750 T1 AT E147750T1 AT 93910147 T AT93910147 T AT 93910147T AT 93910147 T AT93910147 T AT 93910147T AT E147750 T1 ATE147750 T1 AT E147750T1
Authority
AT
Austria
Prior art keywords
biologically active
active compounds
radical
phosphotriester
type
Prior art date
Application number
AT93910147T
Other languages
English (en)
Inventor
Gilles Residence Parc Gosselin
Jean-Louis Lab De Chimi Imbach
Bataillon
Original Assignee
Centre Nat Rech Scient
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR9206383A external-priority patent/FR2691463A1/fr
Application filed by Centre Nat Rech Scient filed Critical Centre Nat Rech Scient
Application granted granted Critical
Publication of ATE147750T1 publication Critical patent/ATE147750T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT93910147T 1992-05-25 1993-05-24 Phosphotriester-typ biologisch-aktiver verbindungen ATE147750T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9206383A FR2691463A1 (fr) 1992-05-25 1992-05-25 Dérivés nucléotidiques, leur préparation et leur application en thérapeutique.
FR9304117A FR2692265B1 (fr) 1992-05-25 1993-04-07 Composes biologiquement actifs de type phosphotriesters.

Publications (1)

Publication Number Publication Date
ATE147750T1 true ATE147750T1 (de) 1997-02-15

Family

ID=26229484

Family Applications (1)

Application Number Title Priority Date Filing Date
AT93910147T ATE147750T1 (de) 1992-05-25 1993-05-24 Phosphotriester-typ biologisch-aktiver verbindungen

Country Status (11)

Country Link
US (2) US6399589B1 (de)
EP (1) EP0642528B1 (de)
JP (1) JP3628324B2 (de)
AT (1) ATE147750T1 (de)
CA (1) CA2136622C (de)
DE (1) DE69307506T2 (de)
DK (1) DK0642528T3 (de)
ES (1) ES2099436T3 (de)
FR (1) FR2692265B1 (de)
GR (1) GR3023130T3 (de)
WO (1) WO1993024510A1 (de)

Families Citing this family (143)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6117847A (en) * 1992-03-16 2000-09-12 Isis Pharmaceuticals, Inc. Oligonucleotides for enhanced modulation of protein kinase C expression
US5849905A (en) * 1994-11-23 1998-12-15 Centre National De La Recherche Scientifique Biologically active phosphotriester-type nucleosides and methods for preparing same
US6174868B1 (en) 1992-09-10 2001-01-16 Isis Pharmaceuticals, Inc. Compositions and methods for treatment of hepatitis C virus-associated diseases
US5985558A (en) * 1997-04-14 1999-11-16 Isis Pharmaceuticals Inc. Antisense oligonucleotide compositions and methods for the inibition of c-Jun and c-Fos
US20020120130A1 (en) 1993-09-10 2002-08-29 Gilles Gosselin 2' or 3' -deoxy and 2', 3' -dideoxy-beta-L-pentofuranonucleo-side compounds, method of preparation and application in therapy, especially as anti- viral agents
CA2637774C (en) 1993-09-10 2011-07-19 Emory University Nucleosides with anti-hepatitis b virus activity
WO1996033201A1 (en) * 1995-04-21 1996-10-24 Centre National De La Recherche Scientifique (Cnrs) Acyclovir derivatives as antiviral agents
FR2733234B1 (fr) * 1995-04-21 1997-07-04 Centre Nat Rech Scient Derives de l'acyclovir comme agents antiviraux
ATE346651T1 (de) 1995-06-07 2006-12-15 Univ Emory Nucleoside mit anti-hepatitis b virus wirksamkeit
US7812149B2 (en) 1996-06-06 2010-10-12 Isis Pharmaceuticals, Inc. 2′-Fluoro substituted oligomeric compounds and compositions for use in gene modulations
US9096636B2 (en) 1996-06-06 2015-08-04 Isis Pharmaceuticals, Inc. Chimeric oligomeric compounds and their use in gene modulation
US5898031A (en) 1996-06-06 1999-04-27 Isis Pharmaceuticals, Inc. Oligoribonucleotides for cleaving RNA
US6716625B1 (en) 1997-04-16 2004-04-06 Claude Selitrennikoff Histidine kinases of Aspergillus and other fungal species, related compositions, and methods of use
US6528271B1 (en) 1997-06-05 2003-03-04 Duke University Inhibition of βarrestin mediated effects prolongs and potentiates opioid receptor-mediated analgesia
US7541151B2 (en) 1997-06-05 2009-06-02 Duke University Single-cell biosensor for the measurement of GPCR ligands in a test sample
WO1999001579A1 (en) 1997-07-01 1999-01-14 Isis Pharmaceuticals, Inc. Compositions and methods for the delivery of oligonucleotides via the alimentary canal
US6133246A (en) * 1997-08-13 2000-10-17 Isis Pharmaceuticals Inc. Antisense oligonucleotide compositions and methods for the modulation of JNK proteins
US6809193B2 (en) 1997-08-13 2004-10-26 Isis Pharmaceuticals, Inc. Antisense oligonucleotide compositions and methods for the modulation of JNK proteins
US5877309A (en) * 1997-08-13 1999-03-02 Isis Pharmaceuticals, Inc. Antisense oligonucleotides against JNK
US6383808B1 (en) 2000-09-11 2002-05-07 Isis Pharmaceuticals, Inc. Antisense inhibition of clusterin expression
US5968748A (en) * 1998-03-26 1999-10-19 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of human HER-2 expression
US6841539B1 (en) 1998-05-21 2005-01-11 Isis Pharmaceuticals, Inc. Compositions and methods for topical delivery of oligonucleotides
US7098192B2 (en) 1999-04-08 2006-08-29 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of STAT3 expression
US20020055479A1 (en) 2000-01-18 2002-05-09 Cowsert Lex M. Antisense modulation of PTP1B expression
US6261840B1 (en) 2000-01-18 2001-07-17 Isis Pharmaceuticals, Inc. Antisense modulation of PTP1B expression
US6684250B2 (en) 2000-04-03 2004-01-27 Quova, Inc. Method and apparatus for estimating a geographic location of a networked entity
US7279324B2 (en) 2001-01-23 2007-10-09 Duke University Nucleic acid encoding G-protein coupled receptor with modified DRY motif
AU2002315393A1 (en) 2001-06-21 2003-01-08 Isis Pharmaceuticals, Inc. Antisense modulation of superoxide dismutase 1, soluble expression
US6964950B2 (en) 2001-07-25 2005-11-15 Isis Pharmaceuticals, Inc. Antisense modulation of C-reactive protein expression
US20030096772A1 (en) 2001-07-30 2003-05-22 Crooke Rosanne M. Antisense modulation of acyl CoA cholesterol acyltransferase-2 expression
US7407943B2 (en) 2001-08-01 2008-08-05 Isis Pharmaceuticals, Inc. Antisense modulation of apolipoprotein B expression
US7227014B2 (en) 2001-08-07 2007-06-05 Isis Pharmaceuticals, Inc. Antisense modulation of apolipoprotein (a) expression
US6750019B2 (en) 2001-10-09 2004-06-15 Isis Pharmaceuticals, Inc. Antisense modulation of insulin-like growth factor binding protein 5 expression
EP2270231A3 (de) 2001-10-09 2011-04-27 ISIS Pharmaceuticals, Inc. Antisense Modulation der Expression von insulin-like growth factor binding protein 5
US6965025B2 (en) 2001-12-10 2005-11-15 Isis Pharmaceuticals, Inc. Antisense modulation of connective tissue growth factor expression
AU2003231765B9 (en) 2002-04-26 2010-01-28 Gilead Sciences, Inc. Cellular accumulation of phosphonate analogs of HIV protease inhibitor compounds and the compounds as such
JP2005538186A (ja) 2002-09-13 2005-12-15 レプリコール インコーポレーティッド 非配列相補性の抗ウイルス性オリゴヌクレオチド
AU2003278957A1 (en) 2002-09-26 2004-04-23 Amgen, Inc. Modulation of forkhead box o1a expression
CA2504720C (en) 2002-11-05 2013-12-24 Isis Pharmaceuticals, Inc. Chimeric oligomeric compounds and their use in gene modulation
WO2004043979A2 (en) 2002-11-05 2004-05-27 Isis Pharmaceuticals, Inc. Sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation
EP2336318B1 (de) 2002-11-13 2013-04-24 Genzyme Corporation Antisense-modulation von apolipoprotein-b-expression
ES2417879T3 (es) 2002-11-13 2013-08-09 Genzyme Corporation Modulación antisentido de la expresión de la apolipoproteína B
US7144999B2 (en) 2002-11-23 2006-12-05 Isis Pharmaceuticals, Inc. Modulation of hypoxia-inducible factor 1 alpha expression
US7468356B2 (en) 2003-02-11 2008-12-23 Antisense Therapeutics Ltd. Modulation of insulin like growth factor I receptor expression
WO2004071453A2 (en) 2003-02-13 2004-08-26 Isis Pharmaceuticals, Inc. Compositions and methods for treatment of pouchitis
US7803781B2 (en) 2003-02-28 2010-09-28 Isis Pharmaceuticals, Inc. Modulation of growth hormone receptor expression and insulin-like growth factor expression
US20040185559A1 (en) 2003-03-21 2004-09-23 Isis Pharmaceuticals Inc. Modulation of diacylglycerol acyltransferase 1 expression
US7598227B2 (en) 2003-04-16 2009-10-06 Isis Pharmaceuticals Inc. Modulation of apolipoprotein C-III expression
WO2004096287A2 (en) 2003-04-25 2004-11-11 Gilead Sciences, Inc. Inosine monophosphate dehydrogenase inhibitory phosphonate compounds
WO2004096233A2 (en) * 2003-04-25 2004-11-11 Gilead Sciences, Inc. Nucleoside phosphonate conjugates
US7470724B2 (en) 2003-04-25 2008-12-30 Gilead Sciences, Inc. Phosphonate compounds having immuno-modulatory activity
US7432261B2 (en) 2003-04-25 2008-10-07 Gilead Sciences, Inc. Anti-inflammatory phosphonate compounds
US7300924B2 (en) 2003-04-25 2007-11-27 Gilead Sciences, Inc. Anti-infective phosphonate analogs
WO2005002626A2 (en) 2003-04-25 2005-01-13 Gilead Sciences, Inc. Therapeutic phosphonate compounds
JP2006524710A (ja) 2003-04-25 2006-11-02 ギリアード サイエンシーズ， インコーポレイテッド キナーゼインヒビターホスホネート抱合体
US7407965B2 (en) 2003-04-25 2008-08-05 Gilead Sciences, Inc. Phosphonate analogs for treating metabolic diseases
US7452901B2 (en) 2003-04-25 2008-11-18 Gilead Sciences, Inc. Anti-cancer phosphonate analogs
PL1628685T3 (pl) 2003-04-25 2011-05-31 Gilead Sciences Inc Przeciwwirusowe analogi fosfonianowe
CN1984921B (zh) 2003-06-03 2010-06-16 Isis药物公司 存活蛋白表达的调节
EP2530157B1 (de) 2003-07-31 2016-09-28 Regulus Therapeutics Inc. Oligomerverbindungen und Zusammensetzungen zur Verwendung bei der Modulation von miRNAs
US7825235B2 (en) 2003-08-18 2010-11-02 Isis Pharmaceuticals, Inc. Modulation of diacylglycerol acyltransferase 2 expression
JP5379347B2 (ja) 2003-09-18 2013-12-25 アイシス ファーマシューティカルズ， インコーポレーテッド ４’−チオヌクレオシドおよびオリゴマー化合物
SG146682A1 (en) 2003-09-18 2008-10-30 Isis Pharmaceuticals Inc Modulation of eif4e expression
US7662929B2 (en) 2003-10-10 2010-02-16 Alchemia Oncology Pty Limited Antibody that specifically binds hyaluronan synthase
US7427624B2 (en) 2003-10-24 2008-09-23 Gilead Sciences, Inc. Purine nucleoside phosphorylase inhibitory phosphonate compounds
WO2005044308A1 (en) 2003-10-24 2005-05-19 Gilead Sciences, Inc. Phosphonate analogs of antimetabolites
AU2004286239A1 (en) 2003-10-24 2005-05-12 Gilead Sciences, Inc. Methods and compositions for identifying therapeutic compounds
JP5838017B2 (ja) 2003-12-03 2015-12-24 コーダ セラピューティクス， インコーポレイテッド コネキシンに対して標的化されたアンチセンス化合物およびその使用方法
DE602004019815D1 (de) 2003-12-22 2009-04-16 Gilead Sciences Inc 4'-substituierte carbovir- und abacavir-derivate sowie verwandte verbindungen mit hiv- und hcv-antiviraler wirkung
US8790919B2 (en) 2004-03-15 2014-07-29 Isis Pharmaceuticals, Inc. Compositions and methods for optimizing cleavage of RNA by RNase H
US8394947B2 (en) 2004-06-03 2013-03-12 Isis Pharmaceuticals, Inc. Positionally modified siRNA constructs
EP1778251B1 (de) 2004-07-27 2011-04-13 Gilead Sciences, Inc. Nukleosid phosphonat konjugate als anti hiv mittel
AU2011218664B2 (en) * 2004-07-27 2014-08-21 Gilead Sciences, Inc. Antiviral compounds
DK1786472T3 (da) 2004-08-10 2013-04-15 Genzyme Corp Antisense-modulering af apolipoprotein B-ekspression
US7884086B2 (en) 2004-09-08 2011-02-08 Isis Pharmaceuticals, Inc. Conjugates for use in hepatocyte free uptake assays
WO2006032143A1 (en) 2004-09-23 2006-03-30 Arc Pharmaceuticals, Inc. Pharmaceutical compositions and methods relating to inhibiting fibrous adhesions or inflammatory disease using low sulphate fucans
NZ554277A (en) 2004-10-20 2010-09-30 Antisense Therapeutics Ltd Antisense modulation of integrin alpha 4 expression
EP2662088A3 (de) 2005-02-03 2014-02-19 Coda Therapeutics Limited Anti-Connexin-Verbindungen und deren Verwendungen
AU2006213686A1 (en) 2005-02-09 2006-08-17 Avi Bio Pharma, Inc. Antisense composition and method for treating muscle atrophy
JP2008544742A (ja) 2005-02-25 2008-12-11 アイシス ファーマシューティカルズ， インコーポレーテッド ＩＬ４Ｒ−αに対する組成物およびその使用
JP2008538355A (ja) 2005-04-08 2008-10-23 アイシス ファーマシューティカルズ， インコーポレーテッド アセチル−ＣｏＡカルボキシラーゼに関する組成物およびそれらの用途
US20060258610A1 (en) 2005-05-12 2006-11-16 Isis Pharmaceuticals, Inc. Modulation of STAT 6 expression for the treatment of airway hyperresponsiveness
EP1888083B1 (de) 2005-05-24 2011-12-28 Isis Pharmaceuticals, Inc. Zusammensetzungen und ihre verwendungen gegen niedermolekulare ptpase
EP1924294A4 (de) 2005-05-24 2010-11-03 Isis Pharmaceuticals Inc Zusammensetzungen und ihre verwendungen gegen ptpru
ES2397113T3 (es) 2005-06-23 2013-03-04 Isis Pharmaceuticals, Inc. Composiciones y procedimientos para modular el corte y empalme de SMN2
US20080076740A1 (en) * 2005-07-27 2008-03-27 Gilead Sciences, Inc. Antiviral compounds
US7700567B2 (en) 2005-09-29 2010-04-20 Supergen, Inc. Oligonucleotide analogues incorporating 5-aza-cytosine therein
SI2161038T1 (sl) 2006-01-26 2014-05-30 Isis Pharmaceuticals, Inc. Sestavki in njihove uporabe, usmerjeni proti huntingtinu
US8076306B2 (en) 2006-04-12 2011-12-13 Isis Pharmaceuticals, Inc. Compositions and their uses directed to hepcidin
MX2008014005A (es) 2006-05-03 2009-01-27 Baltic Technology Dev Ltd Agentes antisentido que combinan un oligonucleotido modificado con base fuertemente unida y nucleasa artificial.
EP2023936A4 (de) 2006-05-05 2010-11-24 Isis Pharmaceuticals Inc Zusammensetzungen und ihre verwendungen in bezug auf ptpr-alpha
EP2505648A1 (de) 2006-05-05 2012-10-03 Isis Pharmaceuticals, Inc. Verbindungen und Verfahren zur Modulation der Expression von PTP1B
DK2021472T3 (da) 2006-05-05 2011-09-19 Isis Pharmaceuticals Inc Forbindelser og fremgangsmåder til modulering af genekspression
JP2010500290A (ja) 2006-08-04 2010-01-07 アイシス ファーマシューティカルズ， インコーポレーテッド Ｊｎｋタンパク質を調節するための組成物および方法
CA2667055C (en) 2006-10-18 2017-05-09 Isis Pharmaceuticals, Inc. Antisense compounds
US7951789B2 (en) 2006-12-28 2011-05-31 Idenix Pharmaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of viral infections
US8048998B2 (en) 2007-01-19 2011-11-01 Exiqon A/S Mediated cellular delivery of LNA oligonucleotides
US8541388B2 (en) 2008-05-22 2013-09-24 Isis Pharmaceuticals, Inc. Methods for modulating expression of RBP4
WO2010014134A1 (en) * 2008-07-02 2010-02-04 Idenix Pharamaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of viral infections
WO2010005850A1 (en) 2008-07-08 2010-01-14 The J. David Gladstone Institutes Methods and compositions for modulating angiogenesis
AU2009268681B2 (en) 2008-07-08 2014-10-02 Gilead Sciences, Inc. Salts of HIV inhibitor compounds
SG196769A1 (en) 2008-08-25 2014-02-13 Excaliard Pharmaceuticals Inc Antisense oligonucleotides directed against connective tissue growth factor and uses thereof
EP2342616A2 (de) 2008-09-23 2011-07-13 Alnylam Pharmaceuticals Inc. Chemische modifikationen von monomeren und oligonukleotiden mit cycloaddition
US20120088814A1 (en) 2009-03-31 2012-04-12 Isis Pharmaceuticals, Inc. Methods of modulating an immune response to a viral infection
WO2011100131A2 (en) 2010-01-28 2011-08-18 Alnylam Pharmacuticals, Inc. Monomers and oligonucleotides comprising cycloaddition adduct(s)
WO2011094580A2 (en) 2010-01-28 2011-08-04 Alnylam Pharmaceuticals, Inc. Chelated copper for use in the preparation of conjugated oligonucleotides
TWI515000B (zh) 2010-04-01 2016-01-01 伊迪尼克製藥公司 用於治療病毒感染之化合物及醫藥組合物
SI2670411T1 (sl) 2011-02-02 2019-06-28 Excaliard Pharmaceuticals, Inc. Protismiselne spojine, ki so usmerjene na rastni faktor veznega tkiva (CTGF), za uporabo v postopku zdravljenja keloidov ali hipertrofnih brazgotin
EP3067421B1 (de) 2011-02-08 2018-10-10 Ionis Pharmaceuticals, Inc. Oligomere verbindungen mit bicyclischen nukleotiden und verwendungen davon
WO2012109495A1 (en) 2011-02-09 2012-08-16 Metabolic Solutions Development Company, Llc Cellular targets of thiazolidinediones
CN103842369A (zh) 2011-03-31 2014-06-04 埃迪尼克斯医药公司 用于治疗病毒感染的化合物和药物组合物
US10202599B2 (en) 2011-08-11 2019-02-12 Ionis Pharmaceuticals, Inc. Selective antisense compounds and uses thereof
AR088441A1 (es) 2011-09-12 2014-06-11 Idenix Pharmaceuticals Inc Compuestos de carboniloximetilfosforamidato sustituido y composiciones farmaceuticas para el tratamiento de infecciones virales
US20130085139A1 (en) 2011-10-04 2013-04-04 Royal Holloway And Bedford New College Oligomers
EP2794624B1 (de) 2011-12-22 2019-05-15 Geron Corporation Guanin-analoga als telomerasesubstrate und telomerlängenaffektoren
CN102613190A (zh) * 2012-03-07 2012-08-01 海南正业中农高科股份有限公司 壳寡糖用于提高坐果率的用途
EP2839006B1 (de) 2012-04-20 2018-01-03 Ionis Pharmaceuticals, Inc. Oligomere verbindungen mit bicyclischen nukleotiden und verwendungen davon
EP2885313A4 (de) * 2012-08-20 2016-03-09 Univ California Polynukleotide mit bioreversiblen gruppen
WO2014059353A2 (en) 2012-10-11 2014-04-17 Isis Pharmaceuticals, Inc. Oligomeric compounds comprising bicyclic nucleosides and uses thereof
WO2014092572A1 (en) 2012-12-12 2014-06-19 Universiteit Leiden Improved methods for cancer treatment with a genotoxic agent
EP3007704B1 (de) 2013-06-13 2021-01-06 Antisense Therapeutics Ltd Kombinationstherapie der akromegalie
KR102275504B1 (ko) 2013-09-05 2021-07-09 사렙타 쎄러퓨틱스, 인코퍼레이티드 산성 알파-글루코시다제 내 안티센스-유도된 엑손2 포함
WO2015190922A1 (en) 2014-06-10 2015-12-17 Erasmus University Medical Center Rotterdam Antisense oligonucleotides useful in treatment of pompe disease
WO2016024205A1 (en) 2014-08-15 2016-02-18 Pfizer Inc. Oligomers targeting hexanucleotide repeat expansion in human c9orf72 gene
WO2016033424A1 (en) 2014-08-29 2016-03-03 Genzyme Corporation Methods for the prevention and treatment of major adverse cardiovascular events using compounds that modulate apolipoprotein b
MA41795A (fr) 2015-03-18 2018-01-23 Sarepta Therapeutics Inc Exclusion d'un exon induite par des composés antisens dans la myostatine
US10849917B2 (en) 2015-06-01 2020-12-01 Sarepta Therapeutics, Inc. Antisense-induced exon exclusion in type VII collagen
EP3316685A4 (de) 2015-07-02 2019-03-13 Otsuka Pharmaceutical Co., Ltd. Lyophilisierte pharmazeutische zusammensetzungen
WO2017062835A2 (en) 2015-10-09 2017-04-13 Sarepta Therapeutics, Inc. Compositions and methods for treating duchenne muscular dystrophy and related disorders
ES2938883T3 (es) 2015-11-05 2023-04-17 Los Angeles Childrens Hospital Oligo antisentido para su uso en el tratamiento de la leucemia mieloide aguda
CA3007152A1 (en) 2015-12-07 2017-06-15 Erasmus University Medical Center Rotterdam Enzymatic replacement therapy and antisense therapy for pompe disease
MY200252A (en) 2016-04-18 2023-12-16 Sarepta Therapeutics Inc Antisense oligomers and methods of using the same for treating diseases associated with the acid alpha-glucosidase gene
NL2017294B1 (en) 2016-08-05 2018-02-14 Univ Erasmus Med Ct Rotterdam Natural cryptic exon removal by pairs of antisense oligonucleotides.
NL2017295B1 (en) 2016-08-05 2018-02-14 Univ Erasmus Med Ct Rotterdam Antisense oligomeric compound for Pompe disease
WO2018035380A1 (en) 2016-08-17 2018-02-22 Solstice Biologics, Ltd. Polynucleotide constructs
WO2019006455A1 (en) 2017-06-30 2019-01-03 Solstice Biologics, Ltd. AUXILIARIES OF CHIRAL PHOSPHORAMIDITIS AND METHODS OF USE THEREOF
US10688112B2 (en) 2017-07-13 2020-06-23 Emory University Lipid disulfide prodrugs and uses related thereto
EP3661937B1 (de) 2017-08-01 2021-07-28 Gilead Sciences, Inc. Kristalline formen von ethyl ((s)-((((2r,5r)-5-(6-amino-9h-purin-9-yl)-4-fluoro-2,5-dihydrofuran-2-yl)oxy)methyl)(phenoxy)phosphoryl)-l-alaninat (gs-9131) zur behandlung von viralen infektionen
EP3661522A2 (de) 2017-08-03 2020-06-10 Otsuka Pharmaceutical Co., Ltd. Arzneimittelverbindung und reinigungsverfahren dafür
JP7282379B2 (ja) * 2017-08-22 2023-05-29 国立大学法人東海国立大学機構 修飾ポリヌクレオチド
WO2019079637A2 (en) 2017-10-18 2019-04-25 Sarepta Therapeutics, Inc. ANTISENSE OLIGOMERIC COMPOUNDS
WO2021020412A1 (ja) 2019-07-30 2021-02-04 塩野義製薬株式会社 Ｍｕｒｆ１を標的とする核酸医薬
CA3152013A1 (en) 2019-08-22 2021-02-25 Emory University Nucleoside prodrugs and uses related thereto

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5430136A (en) 1984-10-16 1995-07-04 Chiron Corporation Oligonucleotides having selectably cleavable and/or abasic sites
DE3650741T2 (de) * 1985-09-17 2000-10-12 The Wellcome Foundation Ltd., Greenford Kombination therapeutische Nukleoside mit weiteren therapeutisch wirksamen Komponenten.
US4968788A (en) 1986-04-04 1990-11-06 Board Of Regents, The University Of Texas System Biologically reversible phosphate and phosphonate protective gruops
SE8704298D0 (sv) * 1987-11-03 1987-11-03 Astra Ab Compounds for use in therapy
FR2654106B1 (fr) * 1989-11-03 1992-01-10 Synthelabo Derives phosphores de cytosine, leur preparation et leur application en therapeutique.
JPH05505941A (ja) * 1990-03-29 1993-09-02 ギリード　サイエンシズ　インコーポレーテッド オリゴヌクレオチド―輸送剤ジスルフィド結合体
AU651835B2 (en) 1990-06-13 1994-08-04 Arnold Glazier Phosphorous prodrugs
US5430138A (en) 1990-07-27 1995-07-04 Chiron Corporation Hydroxyl-protecting groups attached to cytidine nucleotide compounds which are orthogonally removable
EP0481214B1 (de) * 1990-09-14 1998-06-24 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic Wirkstoffvorläufer von Phosphonaten
US5849905A (en) 1994-11-23 1998-12-15 Centre National De La Recherche Scientifique Biologically active phosphotriester-type nucleosides and methods for preparing same
US5770725A (en) 1992-05-25 1998-06-23 Gosselin; Gilles Phosphotriester type biologically active compounds

Also Published As

Publication number Publication date
EP0642528A1 (de) 1995-03-15
US6399589B1 (en) 2002-06-04
DE69307506D1 (de) 1997-02-27
FR2692265B1 (fr) 1996-11-08
CA2136622A1 (fr) 1993-12-09
ES2099436T3 (es) 1997-05-16
GR3023130T3 (en) 1997-07-30
DK0642528T3 (da) 1997-07-21
US6555676B2 (en) 2003-04-29
EP0642528B1 (de) 1997-01-15
CA2136622C (fr) 2006-01-03
JP3628324B2 (ja) 2005-03-09
WO1993024510A1 (fr) 1993-12-09
DE69307506T2 (de) 1997-07-03
US20020037873A1 (en) 2002-03-28
JPH07507068A (ja) 1995-08-03
FR2692265A1 (fr) 1993-12-17

Similar Documents

Publication Publication Date Title
DE69307506D1 (de) Phosphotriester-typ biologisch-aktiver verbindungen
ES2066991T3 (es) Agentes hipoglucemiantes de oxazolidinadiona.
DE3889638D1 (de) Substituierte Propanphosphinsäure-Verbindungen.
ES2175860T3 (es) Procedimiento quimico.
EP0680988A3 (de) Carbamidsäureester-Derivate und diese enthaltende Beschichtungsmassen.
UA27220C2 (uk) Спосіб одержання похідних 1-фенілімідазолін-2,5-діону
FI73969B (fi) Foerfarande foer framstaellning av terapeutiskt aktiva trans-4-aminometylcyklohexankarboxylsyraderivat.
SE7706392L (sv) N-fosfonometylenmonoaminoalkanmono- och -polyfosfonsyror respektive n-fosfonometylendiaminoalkanpolyfosfonsyror samt sett for deras framstellning
CA2026778A1 (en) Dioxaphosphorinane compounds and polyolefin compositions stabilized therewith
FI913067A0 (fi) Bisfosfonsyraderivat, deras framstaellning och anvaendning.
ATE179423T1 (de) Phosphorsubstituierte isoprenderivate
DE3775118D1 (de) Bakterizide zusammensetzungen, die sich auf phosphonsaeurederivaten basieren.
MY104162A (en) A hydrazone compound and production therefor, and an insecticidal composition containing the same.
MX9603616A (es) Derivados de ciclopentadienilo y procesos para su preparacion.
BG92842A (bg) Метод за получаване на бета-карбонил-карбоксиамиди на 1,3-тиазолидини
DE3472961D1 (de) Dihydroxyalkanediphosphonic acids
SE7903687L (sv) Cyklohexylkarboxylsyraderivat och sett att framstella desamma
ES2061822T3 (es) Composiciones de policarbonato hidroliticamente estables.
MY103191A (en) Novel substituted aminomethanediphosphonic acids
MY101645A (en) Phosphoric esters and process for preparing the same.
GR3022546T3 (en) Inositol phosphate analogues as calcium-antagonistic substances
ES8502707A1 (es) Procedimiento para preparar n-fosfonometilglicina
ES8103110A1 (es) Un procedimiento para preparar arilalquil- y ariloxi-alquil-fosfonatos
DE3260015D1 (en) Novel bis- and poly-disulfides having immunostimulant activity
GR3015604T3 (en) Novel organo-tin compounds having anti-tumour activity and anti-tumour compositions.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee